American Society of Clinical Oncology

SHERPA: White

People

  1. Hudis
    Hudis
  2. Scher
    Scher
  3. Motzer
    Motzer
  4. Saltz
    Saltz
  5. Kris
    Kris
  6. Bajorin
    Bajorin
  7. Norton
    Norton
  8. Patil
    Patil
  9. Wolchok
    Wolchok
  10. Morris
    Morris

Groups

  1. Solid Tumor Oncology Division (2144)
  2. Surgery (848)
  3. Genitourinary Disease Management Team (783)
  4. Survivorship Research (754)
  5. Genitourinary Oncology Service (700)
  6. Epidemiology and Biostatistics (624)
  7. Population Sciences Research Program (621)
  8. Breast Cancer Disease Management Team (618)
  9. Gastrointestinal Disease Management Team (601)
  10. Thoracic Malignancies Disease Management Team (572)
Search Within
Refine Results
Formats
  1. Meeting Abstract (2080)
  2. Journal Article (1844)
  3. Conference Paper (1)
Groups
  1. Solid Tumor Oncology Division (2144)
  2. Surgery (848)
  3. Genitourinary Disease Management Team (783)
  4. Survivorship Research (754)
  5. Genitourinary Oncology Service (700)
  6. Epidemiology and Biostatistics (624)

More Groups

People
  1. Robert Motzer (207)
  2. Howard Scher (204)
  3. Clifford Hudis (198)
  4. Leonard Saltz (174)
  5. Dean Bajorin (148)
  6. Mark Kris (143)

More People

Years
  1. 2019 (9)
  2. 2018 (231)
  3. 2017 (114)
  4. 2016 (216)
  5. 2015 (508)
  6. 2014 (446)

More Years

Publications
  1. Journal of Clinical Oncology (3732)
  2. Journal of Oncology Practice (103)
  3. American Society of Clinical Oncology Educational Book (88)
  4. ASCO Connection (1)
  5. ASCO News & Forum (1)

Results (3925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • An open-label phase 1/2a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Saleh, M. N.; Tsai, F. Y. C.; Rosen, L. S.; Adams, B. J.; Liu, L.; Theuer, C. P.; Freddo, J. L.; Agarwal, N.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma
    Meeting Abstract

    Pond, G. R.; Sonpavde, G.; Galsky, M. D.; Sharma, P.; Rosenberg, J. E.; Choueiri, T. K.; Bellmunt, J.; Lee, J. L.; Lee, S. I.; Azrilevich, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • EV-201 study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy
    Meeting Abstract

    Rosenberg, J. E.; Heath, E. I.; O'Donnell, P. H.; Hahn, N. M.; Balar, A. V.; Gartner, E. M.; Melhem-Bertrandt, A.; Petrylak, D. P.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab
    Meeting Abstract

    Pond, G. R.; Niegisch, G.; Rosenberg, J. E.; Dreicer, R.; Powles, T.; Necchi, A.; Wei, X. X.; Grivas, P.; Balar, A. V.; Galsky, M. D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study
    Meeting Abstract

    Petrylak, D. P.; Smith, D. C.; Flaig, T. W.; Zhang, J.; Sridhar, S. S.; Ruether, J. D.; Plimack, E. R.; Merchan, J. R.; Quinn, D. I.; Kilari, D.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification
    Meeting Abstract

    Nguyen, P. L.; Zhang, J. B.; Yousefi, K.; Davicioni, E.; Den, R. B.; Feng, F. Y.; Spratt, D. E.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • IMmotion151: A randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R. J.; Powles, T.; Atkins, M. B.; Escudier, B.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Lee, J. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma
    Meeting Abstract

    Necchi, A.; Mariani, L.; Lo Vullo, S.; Raggi, D.; Giannatempo, P.; Bamias, A.; Crabb, S. J.; Bellmunt, J.; Yu, E. Y.; Niegisch, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study
    Meeting Abstract

    Necchi, A.; Pond, G. R.; Plimack, E. R.; Niegisch, G.; Yu, E. Y.; Pal, S. K.; Bamias, A.; Agarwal, N.; Alva, A. S.; Srinivas, S.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Quality-of-life (QoL) in RANGE: A phase 3 study of ramucirumab (RAM) plus docetaxel (DOC) versus placebo (P) plus DOC in platinum-refractory locally advanced or metastatic urothelial carcinoma (UC)
    Meeting Abstract

    Necchi, A.; Nishiyama, H.; Matsubara, N.; Lee, J. L.; Petrylak, D. P.; De Wit, R.; Drakaki, A.; Liepa, A. M.; Zimmermann, A.; Bell-McGuinn, K. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save